"Pre-treatment strategies can abrogate vasculopathy in models of transplantation and nanotechnological advances may pave the way for future trials in donor organ pretreatment. One of these therapies includes the Targeted Rapamycin Micelles (TRaM) nanoparticle, which targets endothelial cells and has been shown to downregulate immune responses that drive chronic rejection, thereby promoting allograft longevity."
"My dream is that we do organ-recipient matching, that we can pick an organ that's treated in a particular way for that patient, whether it's genetically edited, whether it's given nanotherapy or whether it's given immunometabolic therapy. We can actually tailor the organ for the patient, and this is going to happen."
Feinberg's Alpha Omega Alpha medical honor society chapter held an induction ceremony on March 3, welcoming 41 new members recognized for outstanding educational achievements and professional contributions. Dr. Shilajit Kundu, chief of Urologic Oncology and AOA councilor, welcomed attendees to the 123rd class induction. Dr. Satish Nadig, Edward G. Elcock Professor of Surgical Research and director of the Comprehensive Transplant Center, delivered the keynote lecture addressing chronic rejection in organ transplantation. Nadig discussed how novel organ preservation interventions and pre-treatment strategies can prevent vasculopathy and immune responses. He highlighted the Targeted Rapamycin Micelles nanoparticle therapy, which targets endothelial cells to reduce chronic rejection and extend graft longevity. Nadig envisions future personalized organ-recipient matching through genetic editing, nanotherapy, and immunometabolic approaches.
Read at News Center
Unable to calculate read time
Collection
[
|
...
]